BR112018013808A2 - dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer - Google Patents

dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer

Info

Publication number
BR112018013808A2
BR112018013808A2 BR112018013808-8A BR112018013808A BR112018013808A2 BR 112018013808 A2 BR112018013808 A2 BR 112018013808A2 BR 112018013808 A BR112018013808 A BR 112018013808A BR 112018013808 A2 BR112018013808 A2 BR 112018013808A2
Authority
BR
Brazil
Prior art keywords
cancer
treatment
conditions associated
cyclic dinucleotides
sting activity
Prior art date
Application number
BR112018013808-8A
Other languages
English (en)
Inventor
Glick Gary
Ghosh Shomir
James Olhava Edward
R. Roush William
Jones Roger
Original Assignee
Innate Tumor Immunity, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Tumor Immunity, Inc. filed Critical Innate Tumor Immunity, Inc.
Publication of BR112018013808A2 publication Critical patent/BR112018013808A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

a presente descrição refere-se a compostos de dinucleotídeos que modulam a atividade do estimulador de gene de interferon (sting) para uso, por exemplo, no tratamento de câncer. a presente descrição também apresenta composições, bem como outros métodos de uso e fabricação das mesmas (fórmula (a)). a e b são cada um independentemente selecionados a partir do grupo que consiste nas fórmulas (i), (ii), (iii) e (iv). .
BR112018013808-8A 2016-01-11 2017-01-11 dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer BR112018013808A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277273P 2016-01-11 2016-01-11
US62/277,273 2016-01-11
US201662436759P 2016-12-20 2016-12-20
US62/436,759 2016-12-20
PCT/US2017/013066 WO2017123669A1 (en) 2016-01-11 2017-01-11 Cyclic dinucleotides for treating conditions associated with sting activity such as cancer

Publications (1)

Publication Number Publication Date
BR112018013808A2 true BR112018013808A2 (pt) 2018-12-11

Family

ID=58010371

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018013808-8A BR112018013808A2 (pt) 2016-01-11 2017-01-11 dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer

Country Status (17)

Country Link
US (3) US10604542B2 (pt)
EP (1) EP3402801A1 (pt)
JP (1) JP6867395B2 (pt)
KR (1) KR20180097751A (pt)
CN (1) CN109451740B (pt)
AU (1) AU2017207757B2 (pt)
BR (1) BR112018013808A2 (pt)
CA (1) CA3011528A1 (pt)
CL (1) CL2018001870A1 (pt)
CO (1) CO2018008196A2 (pt)
EA (1) EA036421B1 (pt)
IL (1) IL260427B (pt)
MX (1) MX2018008266A (pt)
MY (1) MY194058A (pt)
PE (1) PE20181330A1 (pt)
SG (1) SG11201805888SA (pt)
WO (1) WO2017123669A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
EP3344644A4 (en) 2015-08-13 2019-02-27 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN109451740B (zh) * 2016-01-11 2022-09-02 先天肿瘤免疫公司 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
KR102530488B1 (ko) 2016-03-18 2023-05-08 이뮨 센서, 엘엘씨 사이클릭 디-뉴클레오티드 화합물 및 사용 방법
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
IL264049B2 (en) 2016-07-06 2023-11-01 Sperovie Biosciences Inc Compounds, preparations and methods for treating the disease
EP3506884B1 (en) 2016-08-30 2021-05-05 Dana-Farber Cancer Institute, Inc. Drug delivery compositions and uses thereof
RS62410B1 (sr) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo[b]tiofenska jedinjenja kao agonisti sting
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018190719A2 (en) 2017-04-13 2018-10-18 Aduro Biotech Holdings, Europe B.V. Anti-sirp alpha antibodies
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
US11259980B2 (en) 2017-07-31 2022-03-01 Arizona Board Of Regents On Behalf Of Arizona State University Soft inflatable exosuit for knee rehabilitation
WO2019027857A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO [B] THIOPHENIC AGONISTS FOR THE TREATMENT OF CANCER
WO2019027858A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. BENZO [B] STING THIOPHEN AGONISTS FOR THE TREATMENT OF CANCER
RU2020112502A (ru) 2017-08-30 2021-10-01 Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. Циклические динуклеотиды в качестве стимулятора модуляторов генов интерферона
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
JP7316263B2 (ja) * 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
KR20200100033A (ko) * 2017-09-14 2020-08-25 얀센 바이오파마, 인크. 변형된 뉴클레오시드 포스포르아미다이트
CN111344297B (zh) * 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
JP7098748B2 (ja) 2017-12-20 2022-07-11 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
EP3505527A1 (en) * 2017-12-29 2019-07-03 Invivogen Cyclic dinucleotides for cytokine induction
US10519187B2 (en) * 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3762397A1 (en) * 2018-03-08 2021-01-13 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3768685A1 (en) 2018-03-23 2021-01-27 Takeda Pharmaceutical Company Limited Sting modulator compounds with sulfamate linkages, and methods of making and using
WO2019195124A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes and related compounds as sting agonists
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
CN111954675A (zh) 2018-04-06 2020-11-17 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
US11008344B2 (en) 2018-07-31 2021-05-18 Incyte Corporation Tricyclic heteroaryl compounds as STING activators
AU2019322722A1 (en) 2018-08-16 2020-10-15 Eisai R&D Management Co., Ltd. Salts of compounds and crystals thereof
TWI825170B (zh) 2018-09-06 2023-12-11 日商第一三共股份有限公司 抗體藥物結合物及其應用及用途
CA3111784A1 (en) 2018-09-12 2020-03-19 Silverback Therapeutics, Inc. Methods and compositions for the treatment of disease with immune stimulatory conjugates
BR112021005208A2 (pt) 2018-09-21 2021-06-08 Shanghai De Novo Pharmatech Co., Ltd. análogo de dinucleotídeo cíclico, composição farmacêutica do mesmo, e aplicação
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
WO2020089815A1 (en) 2018-10-31 2020-05-07 Novartis Ag Antibody conjugates comprising sting agonist
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
KR20210099065A (ko) * 2018-12-04 2021-08-11 브리스톨-마이어스 스큅 컴퍼니 시클릭 디뉴클레오티드의 제조 방법
EP3921323A1 (en) * 2019-02-05 2021-12-15 Bristol-Myers Squibb Company Synthesis of 1,2,5-tri-0-benz0yl-3-dibenzylamin0-3-de0xyrib0se as intermediate for producing 3'-amino-3'-deoxyadenosine and 3'-amino-3'-deoxyguanosine and the protected derivatives thereof
SG11202112223XA (en) 2019-05-10 2021-12-30 Takeda Pharmaceuticals Co Antibody drug conjugates
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CN114206898A (zh) * 2019-07-25 2022-03-18 百济神州有限公司 作为sting激动剂的环状二核苷酸
AU2020358726A1 (en) 2019-10-01 2022-04-07 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
AU2020414031A1 (en) 2019-12-26 2022-07-14 Kyowa Kirin Co., Ltd. Polynucleotide and pharmaceutical composition
JP2023514727A (ja) 2020-02-21 2023-04-07 シルバーバック セラピューティックス インコーポレイテッド ネクチン－４抗体コンジュゲートおよびその使用
EP4115909A1 (en) 2020-03-06 2023-01-11 Daiichi Sankyo Company, Limited Antibody-drug conjugate including novel cyclic dinucleotide derivative
JPWO2021206158A1 (pt) 2020-04-10 2021-10-14
EP4138852A1 (en) * 2020-04-21 2023-03-01 Duke University Compositions and methods for the treatment of pain
WO2021228832A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
WO2022006327A1 (en) 2020-07-01 2022-01-06 Silverback Therapeutics, Inc. Anti-asgr1 antibody conjugates and uses thereof
CN116056765A (zh) 2020-08-07 2023-05-02 坦伯公司 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
CN116113641A (zh) 2020-09-02 2023-05-12 第一三共株式会社 新型内－β－N－乙酰氨基葡萄糖苷酶
KR20230088750A (ko) * 2020-10-15 2023-06-20 더 리젠츠 오브 더 유니버시티 오브 미시건 면역 반응을 조절할 수 있는 금속 이온과 sting 작용제의 결정질 다형 형태
KR102466750B1 (ko) 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022094262A1 (en) 2020-10-30 2022-05-05 Avacta Life Sciences Limited Fap-activated serum extended half-life therapeutic conjugates
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
JPWO2023277168A1 (pt) 2021-06-30 2023-01-05

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2490626A1 (en) 2002-06-20 2003-12-31 Nippon Suisan Kaisha, Ltd. Prodrug, medicinal utilization thereof and process for producing the same
EP1740192B1 (en) * 2004-03-15 2012-06-13 David K. R. Karaolis Cyclic dinucleotide for stimulating the immune of inflammatory response
JP6257607B2 (ja) 2012-06-08 2018-01-10 アデュロ バイオテック，インコーポレイテッド 癌免疫療法のための組成物および方法
EA201590396A1 (ru) 2012-12-13 2015-12-30 Адуро Биотек, Инк. Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
CU24376B1 (es) 2013-04-29 2018-12-05 Memorial Sloan Kettering Cancer Center ANÁLOGOS DE LA GMP-AMP CÍCLICO (cGAMP) ACTIVOS COMO MODULADORES DE LA GMP-AMP CÍCLICO SINTASA (cGAS) Y COMPOSICIONES FARMACÉUTICAS DEL MISMO
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
AP2015008700A0 (en) 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3060056A4 (en) 2013-10-21 2017-10-18 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
US20160287623A1 (en) 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment
US20150144176A1 (en) 2013-11-22 2015-05-28 Massachusetts Institute Of Technology Photovoltaic power balancing and differential power processing
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
AU2015270640B2 (en) 2014-06-04 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of STING
CN107148424B (zh) 2014-12-16 2021-01-08 凯拉治疗股份公司 用于诱导细胞因子的环状二核苷酸
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
EP3344644A4 (en) 2015-08-13 2019-02-27 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
CN109451740B (zh) * 2016-01-11 2022-09-02 先天肿瘤免疫公司 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
KR102530488B1 (ko) 2016-03-18 2023-05-08 이뮨 센서, 엘엘씨 사이클릭 디-뉴클레오티드 화합물 및 사용 방법

Also Published As

Publication number Publication date
US20200165288A1 (en) 2020-05-28
US10604542B2 (en) 2020-03-31
JP2019501204A (ja) 2019-01-17
KR20180097751A (ko) 2018-08-31
IL260427B (en) 2021-03-25
SG11201805888SA (en) 2018-08-30
EA201891565A1 (ru) 2019-01-31
US20210147467A1 (en) 2021-05-20
AU2017207757B2 (en) 2021-05-27
US20190016750A1 (en) 2019-01-17
US10961270B2 (en) 2021-03-30
AU2017207757A1 (en) 2018-08-23
US11505571B2 (en) 2022-11-22
EA036421B1 (ru) 2020-11-09
MX2018008266A (es) 2019-01-31
JP6867395B2 (ja) 2021-04-28
CN109451740B (zh) 2022-09-02
MY194058A (en) 2022-11-10
CA3011528A1 (en) 2017-07-20
EP3402801A1 (en) 2018-11-21
CO2018008196A2 (es) 2018-08-10
PE20181330A1 (es) 2018-08-20
WO2017123669A1 (en) 2017-07-20
CN109451740A (zh) 2019-03-08
CL2018001870A1 (es) 2018-11-30

Similar Documents

Publication Publication Date Title
BR112018013808A2 (pt) dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
ECSP17072474A (es) Métodos para tratar infecciones por el virus filoviridae
EA201991369A1 (ru) Модифицированные направляющие рнк
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
BR112017008696A2 (pt) métodos e composições para células exterminadoras naturais
BR112017006469A2 (pt) composições e métodos para inibição de expressão do gene hao1 (hidroxiácido oxidase 1 (glicolato oxidase))
BR112016021092A2 (pt) Método para provocar uma alteração genética numa célula vegetal e célula vegetal
BR112017019409A2 (pt) forma cristalina de ribosídeo de nicotinamida
NZ714415A (en) Substituted nucleosides, nucleotides and analogs thereof
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
MX2015001871A (es) Celulas asesinas naturales y usos de las mismas.
BR112013033182A2 (pt) compostos imidazopiridinil-aminopiridina substituída
BR112016001783A2 (pt) compostos e composições como inibidores de mek
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112017021700A2 (pt) composições terapêuticas e métodos de uso para o tratamento do câncer
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112014008616A2 (pt) compostos antivirais
BR112017019750A2 (pt) processo para preparação de uma forma cristalina de menaquinol, forma cristalina de menaquinol, processo para preparação de uma forma sólida do menaquinol, composição farmacêutica ou nutracêutica e uso da forma cristalina de menaquinol
BR112018012647A2 (pt) composto, método para tratamento de um hospedeiro, e, uso de um composto.
BR112015016206A2 (pt) moduladores de ship1 e métodos relacionados com os mesmos

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/00 , A61K 31/7084 , A61P 35/00

Ipc: A61K 31/7084 (2006.01), C07H 21/00 (2006.01), A61P

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time